Engineered bacteria modulate tumor-associated macrophages to en-hance immunotherapy
10.12092/j.issn.1009-2501.2025.03.002
- VernacularTitle:工程菌调控肿瘤相关巨噬细胞增强免疫治疗
- Author:
Long WANG
1
;
Yuchen WANG
1
;
Yilin GUO
1
;
Jinhui WU
1
Author Information
1. 南京大学医学院,南京 210093,江苏
- Publication Type:Journal Article
- Keywords:
engineered bacteria;
tumor-associat-ed macrophages;
immunotherapy;
tumor microen-vironment
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(3):297-312
- CountryChina
- Language:Chinese
-
Abstract:
The immunosuppressive tumor micro-environment significantly limits the efficacy of im-munotherapy.Tumor-associated macrophages(TAMs),the most abundant immune cells in the tu-mor microenvironment,often exhibit an immuno-suppressive M2 phenotype,contributing to this im-munosuppressive landscape.Modulating TAMs to adopt anti-tumor phenotypes can enhance immu-notherapy outcomes and inhibit tumor progression.In recent years,tumor immunotherapy leveraging engineered bacteria has garnered considerable at-tention.Bacteria possess the ability to target tu-mors,preferentially colonizing tumor regions,and contain abundant pathogen-associated molecular patterns that effectively activate TAMs within the immunosuppressive tumor environment.This acti-vation enhances the tumoricidal and clearance ca-pabilities of TAMs.With the rapid advancements in synthetic biology,engineered bacteria have emerged as a potent therapeutic modality for im-munotherapy,leading to increased focus on the regulation of TAMs by engineered bacteria.This pa-per first outlines clinical studies on targeted TAMs therapy and engineered bacteria-based tumor ther-apy.It then reviews recent advancements in bacte-rial regulation of TAMs,detailing how engineered bacteria enhance TAM recruitment,improve TAM phagocytosis,and remodel TAM phenotypes.Mod-ulating TAMs with engineered bacteria presents a promising therapeutic strategy and introduces a novel approach in tumor immunotherapy.
